EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
1.6150
-0.0450 (-2.71%)
At close: 03:57PM EDT
1.6200 +0.00 (+0.31%)
After hours: 06:22PM EDT
Stock chart is not supported by your current browser
Previous close1.6600
Open1.6400
Bid1.5100 x 900
Ask1.7600 x 800
Day's range1.5700 - 1.6800
52-week range1.3720 - 5.9600
Volume9,125
Avg. volume18,253
Market cap5.399M
Beta (5Y monthly)0.37
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Evoke Pharma Reports First Quarter 2023 Financial Results

    Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2023, and recent corpo

  • GlobeNewswire

    Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

    Patients treated with Gimoti® (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than patients who were treated with oral metoclopramide Image 1: Nausea and Vomiting or DGP-Related HCRU* Image 2: All-Cause HCRU* Image 3: Likelihood of Utilizing Resource in NMCP Cohort Compared to OMCP Cohort✝ SOLANA BEACH, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty ph

  • GlobeNewswire

    Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

    Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gast

  • GlobeNewswire

    New GIMOTI Patent Listed in FDA Orange Book

    Broad Formulation Patent Expands Protection for GimotiSOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,628,150 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic

  • GlobeNewswire

    United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI

    The Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title “Nasal Formulations of Metoclopramide.” This patent expires in

  • GlobeNewswire

    Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent

    SOLANA BEACH, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI covering its nasal formulation design. Once issued on April 18, 2023, the patent entitled “Nasal Formulation

  • GlobeNewswire

    Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

    Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Image 1 All-Cause HCRU in the Pre-nasal MCP period vs. Post-nasal MCP period Image 2 Nausea, Vomiting, and DGP-associated HCRU in the Pre-nasal MCP period vs. Post-nasal MCP Period SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclo

  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

    Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31,

  • GlobeNewswire

    Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

    SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. Management will host a conference call on Tuesday, March 21, 2023, at 4:30 p.m. ET

  • GlobeNewswire

    Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

    Distinguished event features the year’s best abstracts and invited speakers in their fieldsSOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that its abstract entitled “Reducing Real-World

  • GlobeNewswire

    Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

    Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case FiledSOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI® patent infringement case (Civil Action No. 1:22-cv-02019) in the Uni

  • GlobeNewswire

    Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

    Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTISOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its abstract entitled “Real-World Healthcare Resource Utilization of Patients Treated with Metoclo

  • GlobeNewswire

    USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

    SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.” This patent expires in 2038 and covers the methods for treating moderate-to-

  • GlobeNewswire

    Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

    SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled “Nasal Formulations of Metoclopramide” will expire in December 2029. This

  • GlobeNewswire

    Evoke Pharma Reports Record Third Quarter 2022 Financial Results

    80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2022 and recent corporate developments. “Evoke delivered record fi

  • GlobeNewswire

    Evoke Pharma to Report Third Quarter Results on November 9, 2022

    SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes. Management will host a conference call on Wednesday, November 9, 2022, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 245-3047 and (203)

  • GlobeNewswire

    Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

    Company will exhibit Gimoti® and meet with Key Opinion Leaders Healio Industry Breakthrough Product Award Nominee SOLANA BEACH, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company will participate in the 2022 American College of Gastroenterology Annual Scientific Meeting taking place from October 21 – 26, 2022 in Charlotte, North Carolin

  • GlobeNewswire

    Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI

    SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 16/469,092 for GIMOTI. When granted, the patent will cover methods for treating moderate-to-severe gastroparesis with metoclopramid

  • GlobeNewswire

    GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

    GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey SOLANA BEACH, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its flagship product, GIMOTI

  • GlobeNewswire

    Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference

    SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company’s President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D’Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC. Details of manage

  • GlobeNewswire

    Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution

    Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealthSOLANA BEACH, Calif. and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced that Evoke, through its wide-scale commercialization partner

  • GlobeNewswire

    Evoke Pharma Reports Second Quarter 2022 Financial Results

    Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%SOLANA BEACH, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2022, and recent corporate developments. “Evoke delivered a solid second quarter based o

  • GlobeNewswire

    Evoke Pharma to Report Second Quarter Results on August 10, 2022

    SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022, after the market closes. Management will host a conference call on Wednesday, August 10, 2022, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 343-4849 and (203) 5

  • GlobeNewswire

    Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

    Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced their ongoing collaboration with the International Foundation for Gastrointestinal Disorders (IFFGD) for Gastroparesis Awareness Mo

  • GlobeNewswire

    Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

    SOLANA BEACH, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Canadian Intellectual Property Office granted the Company a key patent for its previously submitted application (CA 2984736) “Nasal Formulations of Metoclopramide.” This new patent corresponds to the two other U.S. Food and